Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management

Journal of Endocrinological Investigation

Volumn 30, Issue 7, 2007, Pages 610-614

  Crepaldi, Gaetano ^a   Carruba, M ^b   Comaschi, M ^c   Del Prato, S ^d   Frajese, G ^e   Paolisso, G ^f  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c West Genoa Hospital   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Incretins; Insulin secretion; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

APOPTOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETIC DIET; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME DEGRADATION; ENZYME INHIBITION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLUENZA; INSULIN RELEASE; INSULIN RESISTANCE; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 35348924943     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346357     Document Type: Review

References (22)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-53.
2. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005, 5: 275-86.
3. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005, 48: 1700-13.
4. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004, 36: 867-76.
5. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 2004, 13: 1091-102.
6. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase4 with antidiabetic properties. Expert Opin Investig Drugs 2006, 15: 431-42.
7. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89: 2078-84.
8. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90: 4888-94.
9. Burkey BF, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005, 315: 688-95.
10. Rolin B. The novel xanthine-based DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in Zucker diabetic fatty rats. Diabetes 2004, 53 (Suppl 2): A341.
11. Mika A. Acute DPP IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Diabetes 2003, 52 (Suppl 1): A350.
12. Sorhede Winzell M, Ahren B. The high-fat fed mouse: a model for studying mechanism and treatment of impaired glucose tolerance and Type 2 diabetes. Diabetes 2004, 53 (Suppl 3): S215-9.
13. Ahren B, Sorhede Winzell M, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol 2005, 521: 164-8.
14. Dardik B. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant Cynomolgus monkeys. Diabetes 2003, 52 (Suppl 1): A322
15. Duttaroy A, Voelker F, Zhang X, et al. The DPP-4 inhibitor vildagliptin increases β cell mass in rodents. Diabetologia 2005, 48 (Suppl 1): A178.
16. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005, 7: 692-8.
17. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 38: 423-8.
18. Ahren B. Gomis R, Standl E, Mills D, Schweizer A. Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27: 2874-80.
19. Garber A, Camisasca R, Ersham E, et al. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A29 (abstract 121-OR).
20. Nathwani A. The use of Vildagliptin for treatment of patients with type 2 diabetes. Late breaking clinical study presented at: 66th Annual Scientific Session of the American Diabetes Association, San Diego, CA, 2005 (http://www.diabetesconnect.org/cgi-bin/store/webcasts⊃eaker).
21. lc during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A29 (abstract 120-OR).
22. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006, 55 (Suppl 1): A111 (abstract 467-P).